Cargando…

Bioactive phospho-therapy with black phosphorus for in vivo tumor suppression

Background and Purpose: Although inorganic nanomaterials have been widely used in multimodal cancer therapies, the intrinsic contributions of the materials are not well understood and sometimes underestimated. In this work, bioactive phospho-therapy with black phosphorus nanosheets (BPs) for in vivo...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Shengyong, Pan, Ting, Zhou, Wenhua, Cui, Haodong, Wu, Lie, Li, Zhibin, Chu, Paul K., Yu, Xue-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163432/
https://www.ncbi.nlm.nih.gov/pubmed/32308745
http://dx.doi.org/10.7150/thno.43092
_version_ 1783523211883839488
author Geng, Shengyong
Pan, Ting
Zhou, Wenhua
Cui, Haodong
Wu, Lie
Li, Zhibin
Chu, Paul K.
Yu, Xue-Feng
author_facet Geng, Shengyong
Pan, Ting
Zhou, Wenhua
Cui, Haodong
Wu, Lie
Li, Zhibin
Chu, Paul K.
Yu, Xue-Feng
author_sort Geng, Shengyong
collection PubMed
description Background and Purpose: Although inorganic nanomaterials have been widely used in multimodal cancer therapies, the intrinsic contributions of the materials are not well understood and sometimes underestimated. In this work, bioactive phospho-therapy with black phosphorus nanosheets (BPs) for in vivo tumor suppression is studied. Methods: Orthotopic liver tumor and acute myeloid leukemia are chosen as the models for the solid tumor and hematological tumor, respectively. BPs are injected into mice through the tail vein and tumor growth is monitored by IVIS bioluminescence imaging. Tumor tissues and serum samples are collected to determine the suppression effect and biosafety of BPs after treatment. Results: The in vitro studies show that BPs with high intracellular uptake produce apoptosis- and autophagy-mediated programmed cell death of human liver carcinoma cells but do not affect normal cells. BPs passively accumulate in the tumor site at a high concentration and inhibit tumor growth. The tumor weight is much less than that observed from the doxorubicin (DOX)-treated group. The average survival time is extended by at least two months and the survival rate is 100% after 120 days. Western bolt analysis confirms that BPs suppress carcinoma growth via the apoptosis and autophagy pathways. In addition, administration of BPs into mice suffering from leukemia results in tumor suppression and long survival. Conclusions: This study reveals that BPs constitute a type of bioactive anti-cancer agents and provides insights into the application of inorganic nanomaterials to cancer therapy.
format Online
Article
Text
id pubmed-7163432
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-71634322020-04-17 Bioactive phospho-therapy with black phosphorus for in vivo tumor suppression Geng, Shengyong Pan, Ting Zhou, Wenhua Cui, Haodong Wu, Lie Li, Zhibin Chu, Paul K. Yu, Xue-Feng Theranostics Research Paper Background and Purpose: Although inorganic nanomaterials have been widely used in multimodal cancer therapies, the intrinsic contributions of the materials are not well understood and sometimes underestimated. In this work, bioactive phospho-therapy with black phosphorus nanosheets (BPs) for in vivo tumor suppression is studied. Methods: Orthotopic liver tumor and acute myeloid leukemia are chosen as the models for the solid tumor and hematological tumor, respectively. BPs are injected into mice through the tail vein and tumor growth is monitored by IVIS bioluminescence imaging. Tumor tissues and serum samples are collected to determine the suppression effect and biosafety of BPs after treatment. Results: The in vitro studies show that BPs with high intracellular uptake produce apoptosis- and autophagy-mediated programmed cell death of human liver carcinoma cells but do not affect normal cells. BPs passively accumulate in the tumor site at a high concentration and inhibit tumor growth. The tumor weight is much less than that observed from the doxorubicin (DOX)-treated group. The average survival time is extended by at least two months and the survival rate is 100% after 120 days. Western bolt analysis confirms that BPs suppress carcinoma growth via the apoptosis and autophagy pathways. In addition, administration of BPs into mice suffering from leukemia results in tumor suppression and long survival. Conclusions: This study reveals that BPs constitute a type of bioactive anti-cancer agents and provides insights into the application of inorganic nanomaterials to cancer therapy. Ivyspring International Publisher 2020-03-26 /pmc/articles/PMC7163432/ /pubmed/32308745 http://dx.doi.org/10.7150/thno.43092 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Geng, Shengyong
Pan, Ting
Zhou, Wenhua
Cui, Haodong
Wu, Lie
Li, Zhibin
Chu, Paul K.
Yu, Xue-Feng
Bioactive phospho-therapy with black phosphorus for in vivo tumor suppression
title Bioactive phospho-therapy with black phosphorus for in vivo tumor suppression
title_full Bioactive phospho-therapy with black phosphorus for in vivo tumor suppression
title_fullStr Bioactive phospho-therapy with black phosphorus for in vivo tumor suppression
title_full_unstemmed Bioactive phospho-therapy with black phosphorus for in vivo tumor suppression
title_short Bioactive phospho-therapy with black phosphorus for in vivo tumor suppression
title_sort bioactive phospho-therapy with black phosphorus for in vivo tumor suppression
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163432/
https://www.ncbi.nlm.nih.gov/pubmed/32308745
http://dx.doi.org/10.7150/thno.43092
work_keys_str_mv AT gengshengyong bioactivephosphotherapywithblackphosphorusforinvivotumorsuppression
AT panting bioactivephosphotherapywithblackphosphorusforinvivotumorsuppression
AT zhouwenhua bioactivephosphotherapywithblackphosphorusforinvivotumorsuppression
AT cuihaodong bioactivephosphotherapywithblackphosphorusforinvivotumorsuppression
AT wulie bioactivephosphotherapywithblackphosphorusforinvivotumorsuppression
AT lizhibin bioactivephosphotherapywithblackphosphorusforinvivotumorsuppression
AT chupaulk bioactivephosphotherapywithblackphosphorusforinvivotumorsuppression
AT yuxuefeng bioactivephosphotherapywithblackphosphorusforinvivotumorsuppression